Uncertainty and variability in human exposure limits – a chemical-specific approach for ciprofloxacin and methotrexate

References

• Abdallah RM, Alam SM, Awaad FM, Dham R, El-Kersh A, El-Laithy A, Shalby MH, et al. Bioequivalence of two brands of ciprofloxacin 750 mg tablets (Sarf and Ciprobay) in healthy human volunteers. Drug Dev Ind Pharm 2002;28:423–429.
   PubMed Web of Science ®Google Scholar
• Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G, Faes C, Vankerckhoven V, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe (1997–2009). J Antimicrob Chemother 2011;66:vi47–vi56.
   PubMedGoogle Scholar
• Albertioni F, Flato B, Seideman P, Beck O, Vinje O, Peterson C, Eksborg S. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995;47:507–511.
   PubMed Web of Science ®Google Scholar
• Allen BC, Kavlock RJ, Kimmel CA, Faustman EM. Dose–response assessment for developmental toxicity. II. Comparison of generic benchmark dose estimates with no observed adverse effect levels. Toxicol Sci 1994;23:487–495.
   Google Scholar
• Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, Mount DR, et al. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 2010;29:730–741.
   PubMed Web of Science ®Google Scholar
• Bailer AJ, Wheeler M, Dankovic D, Noble R, Bena J. Incorporating uncertainty and variability in the assessment of occupational hazards. Int J Risk Assess Manag 2005;5:344–357.
   Google Scholar
• Baird SJS, Cohen JT, Graham JD, Shlyakhter AI, Evans JS. Noncancer risk assessment: a probabilistic alternative to current practice. Hum Ecol Risk Assess 1996;2:79–102.
   Web of Science ®Google Scholar
• Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983;43:2342–2345.
   PubMed Web of Science ®Google Scholar
• Batke M, Escher S, Hoffmann-Doerr S, Melber C, Messinger H, Mangelsdorf I. Evaluation of time extrapolation factors based on the database RepDose. Toxicol Lett 2011;205:122–129.
   PubMed Web of Science ®Google Scholar
• Bender SW, Dalhoff A, Shah PM, Strehl R, Posselt HG. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection 1986;14:17–21.
   PubMed Web of Science ®Google Scholar
• Bercu JP, Parke NJ, Fiori JM, Meyerhoff RD. Human health risk assessments for three neuropharmaceutical compounds in surface waters. Regul Toxicol Pharmacol 2008;50:420–427.
   PubMed Web of Science ®Google Scholar
• Bergan T, Thorsteinsson S, Kolstad I, Johnsen S. Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses. Eur J Clin Microbiol Infect Dis 1986;5:187–192.
   Web of Science ®Google Scholar
• Bokkers BGH, Slob W. A comparison of ratio distributions based on the NOAEL and the benchmark approach for subchronic-to-chronic extrapolation. Toxicol Sci 2005;85:1033–1040.
   PubMed Web of Science ®Google Scholar
• Bokkers BGH, Slob W. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach. Crit Rev Toxicol 2007;37:355–373.
   PubMed Web of Science ®Google Scholar
• Boy D, Well M, Kinzig-Schippers M, Sorgel F, Ankel-Fuchs D, Naber KG. Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. Int J Antimicrob Ag 2004;23:S6–S16.
   Web of Science ®Google Scholar
• Busschaert P, Geeraerd AH, Uyttendaele M, Van Impe JF. Sensitivity analysis of a two-dimensional quantitative microbiological risk assessment: keeping variability and uncertainty separated. Risk Anal 2011;31:1295–1307.
   PubMed Web of Science ®Google Scholar
• Capecchi PL, Blardi P, De Lalla A, Ceccatelli L, Volpi L, Pasini L, Di Perri T. Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. Clin Pharmacol Ther 1995;57:446–454.
   PubMed Web of Science ®Google Scholar
• CBS. Bevolking; geslacht, leeftijd en burgerlijke staat, 1 januari. Centraal Bureau voor Statistiek, Den Haag/Heerlen, the Netherlands; 2012.
   Google Scholar
• Christensson BA, Nilsson-Ehle I, Ljungberg B, Lindblad A, Malmborg AS, Hjelte L, Strandvik B. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1992;36:2512–2517.
   PubMed Web of Science ®Google Scholar
• Chukwuani CM, Coker HA, Oduola AM, Sowunmi A, Ifudu ND. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers. Biol Pharm Bull 2000;23:968–972.
   PubMed Web of Science ®Google Scholar
• Costeff H. A simple empirical formula for calculating approximate surface area in children. Arch Dis Child 1966;41:681–683.
   PubMed Web of Science ®Google Scholar
• Crump B, Wise R, Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 1983;24:784–786.
   PubMed Web of Science ®Google Scholar
• Crump KS. A new method for determining allowable daily intakes. Fundam Appl Toxicol 1984;4:854–871.
   PubMedGoogle Scholar
• Cullen, AC, Frey, HC. Probabilistic techniques in exposure assessment: a handbook for dealing with variability and uncertainty in models and inputs. New York, NY: Plenum Press; 1999.
   Google Scholar
• Cunningham VL, Binks SP, Olson MJ. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regul Toxicol Pharmacol 2009;53:39–45.
   PubMed Web of Science ®Google Scholar
• Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, Smith AL. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987;31:915–919.
   PubMed Web of Science ®Google Scholar
• Davis RL, Koup JR, Williams-Warren J, Weber A, Smith AL. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother 1985;28:74–77.
   PubMed Web of Science ®Google Scholar
• Dekkers S, de Heer C, Rennen MAJ. Critical effect sizes in toxicological risk assessment: a comprehensive and critical evaluation. Environ Toxicol Pharmacol 2001;10:33–52.
   PubMed Web of Science ®Google Scholar
• Di Marco MP, Chen J, Wainer IW, Ducharme MP. A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology. Ther Drug Monit 2004;26:401–407.
   PubMed Web of Science ®Google Scholar
• Dorne JLCM. Metabolism, variability and risk assessment. Toxicology 2010;268:156–164.
   PubMed Web of Science ®Google Scholar
• Dorne JLCM, Walton K, Renwick AG. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment. Food Chem Toxicol 2004;42:275–298.
   PubMed Web of Science ®Google Scholar
• Dorne JLCM, Walton K, Renwick AG. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem Toxicol 2005;43:203–216.
   PubMed Web of Science ®Google Scholar
• Dourson ML, Stara JF. Regulatory history and experimental support of uncertainty (safety) factors. Regul Toxicol Pharmacol 1983;3:224–238.
   PubMedGoogle Scholar
• EFSA. Guidance of the Scientific Committee on a request from EFSA on the use of the benchmark dose approach in risk assessment. EFSA J 2009;1150:1–72.
   Google Scholar
• Epstein M. Aging and the kidney. J Am Soc Nephrol 1996;7:1106–1122.
   PubMed Web of Science ®Google Scholar
• Forrest A, Weir M, Plaisance KI, Drusano GL, Leslie J, Standiford HC. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrob Agents Chemother 1988;32:1537–1540.
   PubMed Web of Science ®Google Scholar
• Förster C, Kociok K, Shakibaei M, Merker HJ, Stahlmann R. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 1996;70:474–481.
   PubMed Web of Science ®Google Scholar
• Foster KR, Vecchia P, Repacholi MH. Risk management. Science and the precautionary principle. Science 2000;288:979–981.
   PubMed Web of Science ®Google Scholar
• Fourtillan JB. Caracteristiques pharmacocinetiques de la ciprofloxacine par voies orale et intraveineuse. Med Maladies Infect 1990;20:33–37.
   Web of Science ®Google Scholar
• Frey HC, Burmaster D. Methods for characterizing variability and uncertainty: comparison of bootstrap simulation and likelihood-based approaches. Risk Anal 1999;19:109–130.
   Web of Science ®Google Scholar
• Frost RW, Lettieri JT, Krol G, Shamblen EC, Lasseter KC. The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin. Clin Pharmacol Ther 1989;45:608–616.
   PubMed Web of Science ®Google Scholar
• Gaylor DW, Kodell RL. Percentiles of the product of uncertainty factors for establishing probabilistic reference doses. Risk Anal 2000;20:245–250.
   PubMed Web of Science ®Google Scholar
• Groeneveld CN, Hakkert BC, Bos PMJ, Heer C. Extrapolation for exposure duration in oral toxicity: a quantitative analysis of historical toxicity data. Hum Ecol Risk Assess 2004;10:709–716.
   Web of Science ®Google Scholar
• Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DGJ. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environ Sci Technol 2008;42:5807–5813.
   PubMed Web of Science ®Google Scholar
• Hall C, Tnham P, Manandhar M, Cheng M, Noble JF, Iatropoulos M. Methotrexate: assessment of in vivo clastogenicity and carcinogenicity. Toxicol Pathol 1988;16:10–21.
   Google Scholar
• Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86–90.
   PubMedGoogle Scholar
• Hassan Y, Alfadly SO, Azmin MN, Peh KK, Tan TF, Noorizan AA, Ismail O. Bioequivalence evaluation of two different formulations of ciprofloxacin tablets in healthy volunteers. Singapore Med J 2007;48:819–823.
   PubMedGoogle Scholar
• Hattis D, Banati P, Goble R. Distributions of individual susceptibility among humans for toxic effects: how much protection does the traditional tenfold factor provide for what fraction of which kinds of chemicals and effects? Ann N Y Acad Sci 1999;895:286–316.
   PubMed Web of Science ®Google Scholar
• Hattis D, Ginsberg G, Sonawane B, Smolenski S, Russ A, Kozlak M, Goble R. Differences in pharmacokinetics between children and adults – II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal 2003;23:117–142.
   PubMed Web of Science ®Google Scholar
• Hattis D, Lynch MK. Empirically observed distributions of pharmacokinetic and pharmacodynamic variability in humans – implications for the derivation of single point component uncertainty factors providing equivalent protection as existing RfDs. In: Lipscomb JC, Ohanian EV, editors. Toxicokinetics in risk assessment. New York: Informa Healthcare USA, Inc.; 2007. pp. 69–93.
   Google Scholar
• Höffler D, Dalhoff A, Gau W, Beermann D, Michl A. Dose- and sex-independent disposition of ciprofloxacin. Eur J Clin Microbiol Infect Dis 1984;3:363–366.
   Web of Science ®Google Scholar
• Hoffman FO, Hammonds JS. Propagation of uncertainty in risk assessments: the need to distinguish between uncertainty due to lack of knowledge and uncertainty due to variability. Risk Anal 1994;14:707–712.
   PubMed Web of Science ®Google Scholar
• Huizer D, Oldenkamp R, Ragas AM, van Rooij JG, Huijbregts MA. Separating uncertainty and physiological variability in human PBPK modelling: the example of 2-propanol and its metabolite acetone. Toxicol Lett 2012;214:154–165.
   PubMed Web of Science ®Google Scholar
• IARC. IARC monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42 – supplement 7. Lyon, France: International Agency for Research on Cancer, World Health Organization; 1987.
   Google Scholar
• Iqbal MP, Baig JA, Ali AA, Niazi SK, Mehboobali N, Hussain MA. The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos 1998;19:163–167.
   PubMed Web of Science ®Google Scholar
• Jeong SH, Song YK, Cho JH. Risk assessment of ciprofloxacin, flavomycin, olaquindox and colistin sulfate based on microbiological impact on human gut biota. Regul Toxicol Pharmacol 2009;53:209–216.
   PubMed Web of Science ®Google Scholar
• Kalberlah F, Schneider K. Quantification of extrapolation factors. Final report of Research Project No. 116 06 113 of the Federal Environmental Agency. Dortmund, Germany: Federal Institute for Occupational Safety and Health; 1998.
   Google Scholar
• Kumar A, Xagoraraki I. Human health risk assessment of pharmaceuticals in water: an uncertainty analysis for meprobamate, carbamazepine, and phenytoin. Regul Toxicol Pharmacol 2010;57:146–156.
   PubMed Web of Science ®Google Scholar
• Kümmerer K, Schuster A, Haiss A, Günther A, Jacobs J, Mohring S, Hamscher G, Simon D. 2009. Umweltrisikobewertung von Zytostatika, Umweltbundesamt, Dessau-Roßlau, Germany.
   Google Scholar
• Kurnik D, Loebstein R, Fishbein E, Almog S, Halkin H, Bar-Meir S, Chowers Y. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003;18:57–63.
   PubMed Web of Science ®Google Scholar
• Lebbe C, Beyeler C, Gerber NJ, Reichen J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994;53:475–477.
   PubMed Web of Science ®Google Scholar
• LeBel M, Bergeron MG, Vallee F, Fiset C, Chasse G, Bigonesse P, Rivard G. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1986a;30:260–266.
   PubMed Web of Science ®Google Scholar
• LeBel M, Vallee F, Bergeron MG. Tissue penetration of ciprofloxacin after single and multiple doses. Antimicrob Agents Chemother 1986b;29:501–505.
   PubMed Web of Science ®Google Scholar
• Lehman AJ, Fitzhugh OG. 100-Fold margin of safety. Assoc Food Drug Off 1954;18:33–35.
   Google Scholar
• Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother 1992;36:993–996.
   PubMed Web of Science ®Google Scholar
• Li P, Cheng NN, Chen BY, Wang YM. In vivo and in vitro chondrotoxicity of ciprofloxacin in juvenile rats. Acta Pharmacol Sin 2004;25:1262–1266.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance. Eur J Clin Microbiol Infect Dis 1989;8:515–520.
   PubMed Web of Science ®Google Scholar
• Lomaestro BM, Bailie GR. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1991;35:1004–1007.
   PubMed Web of Science ®Google Scholar
• Maya MT, Goncalves NJ, Silva NE, Filipe AE, Morais JA. Bioequivalence evaluation of three different oral formulations of ciprofloxacin in healthy volunteers. Eur J Drug Metab Pharmacokinet 2003;28:129–136.
   PubMed Web of Science ®Google Scholar
• Nauta MJ. Separation of uncertainty and variability in quantitative microbial risk assessment models. Int J Food Microbiol 2000;57:9–18.
   Web of Science ®Google Scholar
• OECD. Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents. OECD Publishing; 2008.
   Google Scholar
• Ohbayashi M, Suzuki M, Yashiro Y, Fukuwaka S, Yasuda M, Kohyama N, Kobayashi Y, Yamamoto T. Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro. J Toxicol Sci 2010;35:653–661.
   PubMed Web of Science ®Google Scholar
• Ohnishi M, Hitoshi K, Katoh M, Nadai M, Abe F, Kurono S, Saito H, et al. Effect of a Kampo preparation, byakkokaninjinto, on pharmacokinetics of ciprofloxacin and tetracycline. Biol Pharm Bull 2009;32:1080–1084.
   PubMed Web of Science ®Google Scholar
• Oldenkamp R, Huijbregts MAJ, Hollander A, Versporten A, Goossens H, Ragas AMJ. Spatially explicit prioritization of human antibiotics and antineoplastics in Europe. Environ Int 2013;51:13–26.
   PubMed Web of Science ®Google Scholar
• Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician 2002;65:455–464.
   PubMed Web of Science ®Google Scholar
• Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011;9:517–523.e3.
   PubMed Web of Science ®Google Scholar
• Peltola H, Ukkonen P, Saxen H, Stass H. Single-dose and steady-state pharmacokinetics of a new oral suspension of ciprofloxacin in children. Pediatrics 1998;101:658–662.
   PubMed Web of Science ®Google Scholar
• Peltola H, Vaarala M, Renkonen OV, Neuvonen PJ. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother 1992;36:1086–1090.
   PubMed Web of Science ®Google Scholar
• Pinkerton CR, Welshman SG, Kelly JG, Shanks RG, Bridges JM. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1982;10:36–39.
   PubMed Web of Science ®Google Scholar
• Polk RE, Healy DP, Sahai J, Drwal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841–1844.
   PubMed Web of Science ®Google Scholar
• Price PS, Keenan RE, Swartout JC, Gillis CA, Carlson-Lynch H, Dourson ML. An approach for modeling noncancer dose responses with an emphasis on uncertainty. Risk Anal 1997;17:427–437.
   PubMed Web of Science ®Google Scholar
• Ragas A. Trends and challenges in risk assessment of environmental contaminants. J Integr Environ Sci 2011;8:195–218.
   Web of Science ®Google Scholar
• Ragas AM, Brouwer FP, Buchner FL, Hendriks HW, Huijbregts MA. Separation of uncertainty and interindividual variability in human exposure modeling. J Expo Sci Environ Epidemiol 2009;19:201–212.
   PubMed Web of Science ®Google Scholar
• Ragas AMJ, Huijbregts MAJ. Evaluating the coherence between environmental quality objectives and the acceptable or tolerable daily intake. Regul Toxicol Pharmacol 1998;27:251–264.
   PubMed Web of Science ®Google Scholar
• Renwick AG. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit Contam 1993;10:275–305.
   PubMed Web of Science ®Google Scholar
• Renwick AG, Dorne JLCM, Walton K. Pathway-related factors: the potential for human data to improve the scientific basis of risk assessment. Hum Ecol Risk Assess 2001;7:165–180.
   Web of Science ®Google Scholar
• Renwick AG, Lazarus NR. Human variability and noncancer risk assessment – an analysis of the default uncertainty factor. Regul Toxicol Pharmacol 1998;27:3–20.
   PubMed Web of Science ®Google Scholar
• Schneider K, Schuhmacher-Wolz U, Hassauer M, Darschnik S, Elmshäuser E, Mosbach-Schulz O. A probabilistic effect assessment model for hazardous substances at the workplace. Regul Toxicol Pharmacol 2006;44:172–181.
   PubMed Web of Science ®Google Scholar
• Schriks M, Heringa MB, van der Kooi MME, de Voogt P, van Wezel AP. Toxicological relevance of emerging contaminants for drinking water quality. Water Res 2010;44:461–476.
   PubMed Web of Science ®Google Scholar
• Schwab BW, Hayes EP, Fiori JM, Mastrocco FJ, Roden NM, Cragin D, Meyerhoff RD, et al. Human pharmaceuticals in US surface waters: a human health risk assessment. Regul Toxicol Pharmacol 2005;42:296–312.
   PubMed Web of Science ®Google Scholar
• Shao K, Gift JS, Setzer RW. Is the assumption of normality or log-normality for continuous response data critical for benchmark dose estimation? Toxicol Appl Pharmacol 2013;272:767–779.
   PubMed Web of Science ®Google Scholar
• Slob W. Uncertainty analysis in multiplicative models. Risk Anal 1994;14:571–576.
   Web of Science ®Google Scholar
• Slob W. Dose–response modeling of continuous endpoints. Toxicol Sci 2002;66:298–312.
   PubMed Web of Science ®Google Scholar
• Slob W, Pieters MN. A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: general framework. Risk Anal 1998;18:787–798.
   PubMed Web of Science ®Google Scholar
• Slob W, Setzer RW. Shape and steepness of toxicological dose–response relationships of continuous endpoints. Crit Rev Toxicol 2014;44:270–297.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Schultz FW, Nooter K, Hahlen K. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother Pharmacol 1986;18:111–116.
   PubMed Web of Science ®Google Scholar
• Stephens MC, Baldassano RN, York A, Widemann B, Pitney AC, Jayaprakash N, Adamson PC. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005;40:445–449.
   PubMed Web of Science ®Google Scholar
• Stuht H, Lode H, Koeppe P, Rost KL, Schaberg T. Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Ch 1995;39:1045–1049.
   PubMed Web of Science ®Google Scholar
• Thuo N, Ungphakorn W, Karisa J, Muchohi S, Muturi A, Kokwaro G, Thomson AH, Maitland K. Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. J Antimicrob Chemother 2011;66:2336–2345.
   PubMed Web of Science ®Google Scholar
• Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65:168–173.
   PubMedGoogle Scholar
• TOXNET. Hazardous Substances Data Bank (HSDB). Available from: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB. Accessed at 15 Sep 2015. U.S. National Library of Medicine; 2015.
   Google Scholar
• Travis KZ, Pate I, Welsh ZK. The role of the benchmark dose in a regulatory context. Regul Toxicol Pharmacol 2005;43:280–291.
   PubMed Web of Science ®Google Scholar
• US FDA. Drug label for CIPRO®, NDA no. 019537. US Food and Drug Administration, Center for Drug Evaluation and Research; 2013.
   Google Scholar
• US EPA. Risk Assessment Guidance for Superfund: Volume III – Part A, Process for conducting probabilistic risk assessment. Washington, DC: United States Environmental Protection Agency; 2001.
   Google Scholar
• Vakily M, Amer F, Kukulka MJ, Andhivarothai N. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J Clin Pharmacol 2005;45:1179–1186.
   PubMed Web of Science ®Google Scholar
• Van Der Voet H, Slob W. Integration of probabilistic exposure assessment and probabilistic hazard characterization. Risk Anal 2007;27:351–371.
   PubMed Web of Science ®Google Scholar
• Vermeire T, Stevenson H, Pieters MN, Rennen M, Slob W, Hakkert BC. Assessment factors for human health risk assessment: a discussion paper. Crit Rev Toxicol 1999;29:439–490.
   PubMed Web of Science ®Google Scholar
• von Keutz E, Ruhl-Fehlert C, Drommer W, Rosenbruch M. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol 2004;78:418–424.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Kinzig-Schippers M, Sorgel F, Weidner W, Naber KG. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose. Int J Antimicrob Ag 2006;28:551–559.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sorgel F, Naber KG. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 2003;47:3789–3794.
   PubMed Web of Science ®Google Scholar
• Walker WE, Harremoës P, Rotmans J, van der Sluijs JP, van Asselt MBA, Janssen P, Krayer von Krauss MP. Defining uncertainty: a conceptual basis for uncertainty management in model-based decision support. Integr Assess 2003;4:5–17.
   Google Scholar
• Washington C, Hou E, Hughes N, Berner B. Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin. Am J Health Syst Pharm 2006;63:653–656.
   PubMed Web of Science ®Google Scholar
• Webb S, Ternes T, Gibert M, Olejniczak K. Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 2003;142:157–167.
   PubMed Web of Science ®Google Scholar
• WHO. Guidance Document on Evaluating and Expressing Uncertainty in Hazard Characterization, WHO, IPCS Harmonization Project; no. 11; 2014.
   Google Scholar
• Wise R, Lister D, Mcnulty CA, Griggs D, Andrews JM. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin. Infection 1986;14:S196–S202.
   PubMed Web of Science ®Google Scholar
• Woutersen RA, Jonker D, Stevenson H, Te Biesebeek JD, Slob W. The benchmark approach applied to a 28-day toxicity study with Rhodorsil Silane in rats: the impact of increasing the number of dose groups. Food Chem Toxicol 2001;39:697–707.
   PubMed Web of Science ®Google Scholar
• Wu FC, Tsang YP. Second-order Monte Carlo uncertainty/variability analysis using correlated model parameters: application to salmonid embryo survival risk assessment. Ecol Model 2004;177:393–414.
   Web of Science ®Google Scholar
• Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Frost RW. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Ch 1989;33:1118–1120.
   PubMed Web of Science ®Google Scholar